hotspot -WSS

hotspot

author：hotspot 2025-09-27 12:47:52 - browse：3

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Wikipedia

WSS

White House finalizes ITC's import ban of latest Apple Watches

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

CZI to create biohub to build anti

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Roche drug slashes death risk in early

U.K. sequencing study surfaces new findings about tumor DNA

leisure time

hotspot

leisure time

Apple is now the first public company to be valued at $3 trillion

3 trends to watch in health tech's hiring outlook for 2024

Heart attack and stroke risk calculators need revising

ADCs take center stage as promising cancer treatments

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Activists slam private health insurers over coverage restrictions

Chronically ill young patients struggle to find fertility info

Malaria cases in Florida and Texas: Here’s what you need to know

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

entertainment

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Roivant's CEO is a star, but biotech's black hole persists

Why a market frenzy over new weight loss drugs defies logic

FDA clears Verve to begin U.S. study of gene

How a scoliosis diagnosis changed the life of one young dancer

A single drug, study failures leave Anavex with nothing but cash

Wikipedia

explore

entertainment

Wikipedia